
We are a global leader in cardiology, and we have chosen to become a focused and innovative player in oncology by 2030, targeting difficult-to-treat cancers and dedicating over 70% of our R&D budget to it.
We are a human-sized pharmaceutical group with an international presence and a Foundation-based governance model. Our unique approach allows us to serve our vocation of
We are a global leader in cardiology, and we have chosen to become a focused and innovative player in oncology by 2030, targeting difficult-to-treat cancers and dedicating over 70% of our R&D budget to it.